65,437 trials
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Primary Bioequivalence Analysis - Area Under the Curve Within a 28-day Dosing Interval (AUC0-28) in Adult Subjects — 1.01; 1.01; 1.07; 1.07 ratio Gammaplex 10%/Gammaplex…
Endotracheal Extubation · Airway Obstruction · Airway Control
Primary: Percentage of Occlusion Assessed Using a High Definition Computed Tomography Imaging of the Extubated ETTs — 10.6; 17.7 percentage of occlusion
Ankle Injuries
Primary: Percentage of Nonpalpable Hardware — 71; 55; 64; 66 percentage of participants
Autistic Disorder
Primary: Number of Participants With Adverse Events Reported on the Dosage Record and Treatment Emergent Symptom Scale (DOTES) — 17 number of participants
Primary Immunodeficiency Disease
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug — 19.0 Percentage of participants
Chronic Kidney Disease Stage 3 and 4
Primary: Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax) — 0.13 ng/mL
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-Free Survival (EFS) — 48.1; 62.9 Percentage of participants — p=0.1016
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
Alcoholism
Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Acamprosate or Naltrexone or Placebo During the Double-Blind Period — 2.12; 3.40; 5.86…
Adult Glioblastoma Multiforme
Primary: Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6) — 12.5; 7.5 percentage of participants
Tonsillitis
Primary: Self-reported Pain Score — 5.0; 6.0; 5.1; 6.0 pain score (units on a scale) — p=.674
Prostate Cancer
Primary: Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 events
Larynx Disease · Gastroesophageal Reflux
Primary: Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy — 0 participants
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Adverse Events — 98.0 percentage of participants
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants